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Abstract
Background: Communicating the results of randomised controlled trials may present challenges for researchers
who have to work with communities and policy-makers to anticipate positive outcomes, while being aware that
results may show no effect or harm.
Methods: We present a case study from the perspective of researchers in South Africa about the lessons learnt
from communicating the results of four trials evaluating treatment for herpes simplex virus type 2 (HSV-2) as a new
strategy for HIV prevention.
Results: We show that contextual factors such as misunderstandings and mistrust played an important role in
defining the communications response. Use of different approaches in combination was found to be most
effective in building understanding, credibility and trust in the research process. During the communication
process, researchers acted beyond their traditional role of neutral observers and became agents of social change.
This change in role is in keeping with a global trend towards increased communication of research results and
presents both opportunities and challenges for the conduct of future research.
Conclusions: Despite disappointing trial results which showed no benefit of HSV-2 treatment for HIV prevention,
important lessons were learnt about the value of the communication process in building trust between
researchers, community members and policy-makers, and creating an enabling environment for future research
partnerships.
Background
Randomised controlled trials are considered the gold
standard for evaluating the effectiveness of new inter-
ventions. Communicating the results of these trials may
present challenges for researchers who need to work
with stakeholders to prepare for potentially positive out-
comes, while at the same time living with the knowledge
that trials may show no effect, or even harm.
International development agencies are placing
increasing emphasis on the need to communicate
research results to policy-makers. In rational models of
policy development, researchers conduct research to
provide evidence to guide policy change. Once the
research is completed, there is an expectation that pol-
icy-makers will either accept the evidence or that
informed advocates will use the evidence to lobby for
policy change. In this model, researchers are tradition-
ally regarded as neutral observers. In low- and middle-
income countries, there may be challenges to this
model. In these settings, researchers may be influenced
by the political context and be drawn into the process
of advocating for policy and social change.
In this case study about communicating the results of
four trials of herpes simplex virus type 2 (HSV-2)
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treatment for HIV prevention in South Africa, we reflect
on the interactions between researchers and society, and
the role of researchers as agents of social change.
Methods
This case study was written from a researcher perspec-
tive. It represents the accumulated experience, reflec-
tions and discussions of the authors over the life of
these four trials. All the authors were involved in differ-
ent ways in the results communication process, and
have first-hand experience of presenting these results to
the different audiences outlined in the paper.
A first draft of this paper was presented at a workshop
on Research-to-Policy processes in Liverpool, United
Kingdom in May 2009. Earlier drafts which described
the communications process were presented at investi-
gators’ meetings for the multi-centred trials. Feedback
from participants at these meetings was used in the
development of this paper. In addition, the authors
referred back to research dissemination plans drafted
prior to trial completion, as well as reports written by
staff which recorded various aspects of the results com-
munication process, including reactions to the process
by stakeholders.
Setting and context
South Africa has one of the highest rates of new HIV
infections in the world, despite over a decade of invest-
ment in primary prevention [1]. Combating HIV
remains an important Millennium Development Goal
yet to be achieved [2]. The high incidence of HIV, along
with a relatively well-developed infrastructure, and a
new commitment to human rights culture provide the
ideal environment for research into new HIV prevention
interventions. Despite this, there are several challenges
to conducting research in this context.
The apartheid history of South Africa has left a legacy
of suspicion and mistrust of research. At the centre of
this suspicion is the recurring theme of conspiracy
against Africans, either from the country’s white conser-
vatives or from the pharmaceutical industry [3,4]. With
respect to HIV/AIDS, this is articulated in the notion
that the AIDS epidemic was conceived as a plot of the
apartheid government to eradicate the black population
[4,5]. While conspiracy theories may seem unfounded,
they have their genesis in historical reality. It has been
reported that in the final days of the apartheid regime,
government laboratories were involved in attempting to
spread HIV through a network of infected sex workers,
amongst other things [3]. In the past decade, the debate
over the origins of AIDS has highlighted the longstand-
ing tensions between the scientific method, espoused by
modern biomedical models, and indigenous knowledge
systems. These tensions are best evidenced by the
regular clashes between the Treatment Action Cam-
paign and the Minister of Health, but extend throughout
South African society [6].
Another legacy of apartheid is a skills shortage. This is
evident in government where there is insufficient experi-
ence and skill to interpret and use research evidence to
inform policy at local, provincial and national levels of
government. Most communities in South Africa are
relatively research-naïve. Those communities where
research is conducted are often poor, have limited
access to education and are experiencing the brunt of
the burden of HIV. Although they may be suspicious of
research, they recognise the need to respond to HIV
and see research as one way to do this. However, these
communities often have very little experience or insight
into the research process and may have unrealistic
expectations of what can be achieved. The media is fre-
quently unable to assist or contribute constructively to
the debate, and in some instances may fuel suspicion
and mistrust of research [7].
In this context it is not surprising that researchers are
frequently drawn into mediating these tensions between
stakeholders, rather than playing the more traditional
role of a “neutral observer”. In establishing and imple-
menting HIV prevention trials in South Africa, research-
ers are required to build trust and address the historical
stereotype of researchers as villains. They also have to
manage the popular perception of biomedical certainty,
i.e., that that modern medicine has all the answers. They
are required to explain the scientific method and man-
age the expectations of sometimes desperate commu-
nities. They need to anticipate the outcomes of these
trials, and support policy-makers to do the same so that
research results can be rapidly translated into pro-
grammes. At the same time, they must recognise and
work within the limitations of an ailing health service.
Description of the trials
Four trials evaluating treatment for herpes simplex virus
type 2 (HSV-2) were conducted in Johannesburg from
2004-2008. The trials evaluated different treatment stra-
tegies (episodic therapy or suppressive therapy using the
antiherpetic drug acyclovir) and involved populations
(men, women, couples) who were either HIV uninfected
or HIV infected and were designed to answer a range of
questions about the potential role of herpes treatment
for HIV prevention (see table 1). These trials were
developed following observational data that HSV-2
increases the risk for HIV acquisition [8], and that in
dually infected individuals, HSV-2 infection increases
HIV replication and potentially transmission [9]. How-
ever, randomised controlled trials were required to test
this hypothesis using an experimental design in order to
prove the causal relationship between HSV-2 infection
Delany-Moretlwe et al. Health Research Policy and Systems 2011, 9(Suppl 1):S8
http://www.biomedcentral.com/1478-4505/9/S1/S8
Page 2 of 9
and HIV transmission. In South Africa, all these trials
were submitted through the usual regulatory processes
and approved by the University of the Witwatersrand
Human Research Ethics Committee and the Medicines
Control Council of South Africa.
Results
Context influenced the approach to communication
Our approach to communication was an organic pro-
cess, but was shaped early on by several formative
events. One event was the early closure of the male cir-
cumcision trial in Orange Farm due to evidence of effi-
cacy. In this trial, male circumcision was shown to
reduce the risk of HIV acquisition in men by 60% [10].
Despite the positive findings, the approach to communi-
cation of results to communities was modest. The delays
in developing and adopting a national policy on male
circumcision based on evidence obtained from South
Africa illustrated the importance of anticipating a posi-
tive trial outcome and laying the foundation for rapid
translation of research into HIV prevention policy and
programmes.
Another important event was the highly publicised
early closure of the cellulose sulphate microbicide trial.
The trial was closed on the advice of the Data Safety
and Monitoring Committee after an interim analysis
which showed a higher number of HIV seroconversions
in the microbicide arm compared to the placebo arm
[11]. The ensuing negative media coverage with several
sensationalist and inaccurate headlines [7,12], created
fear and confusion in trial participants and their com-
munities, as well as among South Africans more gener-
ally. The response of the Department of Health was to
call for an investigation into the ethical conduct of these
trials. While this action was welcomed by investigators,
it fuelled suspicions in the public mind that participants
were exploited and the trial was unethical, which was
not correct. Throughout the furore, the voices of trial
participants and communities were seldom heard, with
journalists and government officials often speaking on
their behalf. This experience emphasized the need to
prepare staff, participants and communities for all possi-
ble trial outcomes, to work with communities to ensure
that their voices are heard in future debates, and to
work with experienced objective journalists when telling
these stories.
A third event was the success of the civil society orga-
nisation, the Treatment Action Campaign in successfully
challenging the Department of Health in the Constitu-
tional Court to ensure access to nevirapine for all preg-
nant HIV-positive women to prevent the transmission
of HIV from mother-to-child. The success of the mobili-
sation of communities behind evidence-based policies
and programmes demonstrated the value of informed
and engaged communities. Together these three experi-
ences highlighted the importance of participants and
communities as advocates of research, as well as of
potentially successful HIV prevention technologies. So,
when interactions with government officials became
more difficult as a result of the influence of the Minister
of Health and other AIDS denialists, our focus shifted
away from engagement with policy-makers towards
building stronger partnerships with communities.
Building credibility through linkages
We established community advisory boards (CAB) in
the trial sites. These were formed following an initial
community consultation workshop to which representa-
tives from a wide range of community-based organisa-
tions (CBO) identified during several mapping exercises
as active in the trial site, were invited. Research staff
provided explanations about the organisation, the
research process and the importance of community par-
ticipation in the research process. Information about the
Table 1 Summary of design and outcomes of trials investigating the role of treatment for herpes simplex virus type 2
(HSV-2) for HIV prevention
Author Study design & population Intervention Expected Outcome
Trials of HSV-2 suppressive therapy
Celum
et al., 2008
Randomised, double blind, placebo-controlled trial in 3172 HIV-negative,
HSV-2–positive participants (1358 women, 1814 men who have sex with
men)
Acyclovir, 400 mg twice
daily, for 12–18 months
Prevention of HIV acquisition
Delany
et al., 2009
Randomized, double-blind, placebo-controlled trial in 299 HIV-positive,
HSV-2–positive women with CD4 > 250 not on HAART in South Africa
Acyclovir, 400 mg twice
daily, for 3 months
Reduction of HIV
infectiousness
Celum
et al., 2009
Randomised, double blind, placebo-controlled trial in 3408 HIV-1 /
HSV-2 dually-infected persons within HIV-1 serodiscordant Couples
Acyclovir, 400 mg twice
daily, for 12-24 months
Prevention of HIV
transmission and disease
progression
Trials of HSV-2 episodic therapy
Paz-Bailey
et al., 2009
Randomised, double blind, placebo-controlled trial in 615 men with genital
ulcer disease
Acyclovir 400mg three
times a day, for 5 days
Reduction of HIV
infectiousness Increased
ulcer healing
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intention to conduct HIV prevention research was also
provided. Thereafter, participants were asked to consult
their organisations about future representation in a
CAB. At a subsequent meeting, volunteers who repre-
sented either themselves or CBOs were included in the
CAB. Terms of reference, agreed to by all members,
guided the operation of the CAB, which was facilitated
by research staff. CAB members were trained in
research ethics and the specific details of the trial proto-
cols. Monthly meetings were held to provide updates on
the trials and to discuss progress and challenges. These
meetings were also used to present on other research
projects in the district. CAB members were able to
interrogate protocols and ask probing questions of other
investigators, for example, “Is it ethical to use a pla-
cebo?” or “What will you do about access to treatment
after the trial?” These questions indicated a growing
level of insight into the research process over time.
Over time, we used multiple means of communication
to explain the trials and the rationale for doing them
including drama, music, radio and community events.
These events provided opportunities for research staff to
engage regularly with participants and community mem-
bers about the trials and the rationale for doing them.
Working with two local community radio stations, we
developed a weekly one-hour phone-in radio show
which dealt with sexual and reproductive health topics,
including HIV. Through these shows the health infor-
mation needs of communities were addressed, but more
importantly a dialogue between the researchers and the
community was established.
As the trials progressed, it became important to con-
sider what the implications of a positive outcome would
mean for future programmes. The experiences of parti-
cipants in the four trials allowed us to respond to chal-
lenges from critics that daily acyclovir would not be
feasible as an HIV prevention intervention. We con-
ducted additional research which informed questions
around access to drug, cost and cost-effectiveness, test-
ing strategies and whom to target for intervention, as
well as how best to ensure optimal treatment adherence.
Investigators worked with international agencies such as
the World Health Organisation (WHO) to inform the
development of several guidelines for the use of herpes
therapy. As the South African National AIDS Council
(SANAC), which encompasses representatives from gov-
ernment and 17 sectors of civil society, was revived,
investigators were also able to make presentations to
this body and its committees about the trials and the
need to consider the implications of a positive outcome
for the National Strategic Plan and HIV prevention
programmes.
As the results from other trials in Africa became avail-
able [13,14], discussions with participants and
communities focussed on planning for access to acyclo-
vir for former trial participants and ensuring access to
care for those who were HIV positive. The importance
of completing all the trials in order to answer all the
research questions was also emphasised. For many com-
munity members, the message that these were trials and
not health programmes only began to set in as the first
of the trials closed. Seeing the experiences of others
helped to focus staff and community members on plan-
ning for all possible trial outcomes. At this stage, media
training for staff and CAB members by media experts
helped to consolidate key messages about the trials for
all possible outcome scenarios. For both staff and com-
munity members the idea that the trials might not show
an effect was still a difficult one, despite the training
that they had received about the nature of randomised
controlled trials. This observation that staff, participants
and community members were heavily invested in a
positive outcome showed how important these trials
were at a personal level in terms of the hope they repre-
sented to people in the fight against HIV.
Communicating the evidence
The first of the four trials’ results from Johannesburg
were available in early 2007, and the results from the
final trial were released in May 2009. Over the two-year
period, we developed an approach to communicating
research results which included a set of activities com-
mon to all trials. However, in communicating the results
of four trials this process became iterative and allowed
us to modify and refine our approach based on previous
experiences. The fact that the trials were examining dif-
ferent aspects of the interactions between HSV-2 and
HIV allowed us to build a narrative that assisted with
communicating these relatively complex results to stake-
holders over time.
Central to the communication process was the devel-
opment of a communication plan. This plan mapped
out the target audiences, as well as the timing and
means of communication. The plan became more
sophisticated with each successive trial that was com-
municated. In terms of audience, three main groups
with slightly different communication needs were identi-
fied, namely trial participants, the CAB and community
members, and then other stakeholders who included the
Department of Health, regulatory bodies such as the
Research Ethics Committee (REC) and the Medicines
Control Council (MCC), other interested parties includ-
ing other researchers and organisations dealing with
HIV, and selected health and science journalists. Timing
of communication was also a critical consideration.
There was an attempt to communicate the results of the
trial to participants, CAB and key stakeholders in the
Department of Health, the REC and the MCC at least
Delany-Moretlwe et al. Health Research Policy and Systems 2011, 9(Suppl 1):S8
http://www.biomedcentral.com/1478-4505/9/S1/S8
Page 4 of 9
24 hours before the public announcement of trial results
either by press release or at a conference. The purpose
of this exercise was to forewarn all three groups of the
results so that they were not caught unawares. In the
case of the CAB and key stakeholders, this gave them
time to prepare responses to the results if needed. The
narrow time-frame and the need to protect the confi-
dentiality of results during this period also determined
the means of communication. For participants, commu-
nication of approved messages via short message service
on cellular phones proved successful. In some cases,
these messages were also delivered to CAB members,
although it was easier to have face-to-face meetings with
CAB members. For pre-release contacts with the
Department of Health, REC and MCC, the actual results
also influenced the means of communication. Generally,
these groups were not available for face-to-face meetings
unless there were important policy changes arising from
the results. With these trials, communication was gener-
ally by telephone communication but in some cases
email communication was sufficient.
After their initial public release results continued to be
communicated primarily through a series of face-to-face
events. Workshops were held for participants and com-
munity members where results were presented in local
languages and using drawings or images to illustrate
important concepts. Questions and responses were
documented so that messages for subsequent workshops
could be refined. Central to all the communication
activities was a combined workshop, which brought
together the researchers, participants and community
members, the Department of Health and other research-
ers or organisations dealing with HIV, to discuss the
trial results and the implications for policy and pro-
grammes from all perspectives. At one such event a par-
ticipant spontaneously disclosed her role as a trial
participant, her positive experience of the trial and the
benefits of herpes treatment on her life. She was able to
ask the Department of Health official what the implica-
tions of the trial would mean for access to acyclovir at
primary health care clinics. For the researchers, this
example best illustrated the value of engaging with par-
ticipants and community members and helping them to
develop the knowledge and skills to advocate for new
health interventions. Another important face-to-face
activity was the introduction of ‘unblinding visits’. At
these visits, trial staff counselled participants on the
results of the trial and their treatment allocation arm,
using an ‘unblinding’ script approved by the REC. Parti-
cipant responses to their ‘unblinding’ were documented
in patient files. Responses were monitored and reported
in internal project reports. Despite all the communica-
tion activities, the majority of participants said at the
unblinding interview that they had not heard the trial
results. Generally, participants accepted the information
about their trial. Some participants however reported
feeling disappointed or in some cases cheated. Partici-
pants reported “forgetting” that there was a placebo
arm. During subsequent discussion, participants
acknowledged that they recalled the informed consent
discussion and did understand that there was a placebo
arm, but could not believe that staff would give them
the placebo. Some participants said that they expected
that the placebo would look different. Some participants
did not believe that they were on the placebo arm
because they had experienced improvements in symp-
toms. Others did not believe that they were on placebo
because their study drug bottle was labelled acyclovir
(the label actually said “acyclovir/placebo 400 mg”).
These interviews revealed the difference between partici-
pants intellectual versus their experiential knowledge of
the trial [15] and illustrated the importance of persona-
lising the trials results for the individuals, as well as
reiterating concepts specific to trials like blinding, ran-
domisation and placebo which were originally discussed
during the informed consent process.
Not surprisingly, in the build up to communicating
the trial results there were anxieties about dealing with
the media and the media responses. In order to manage
this relationship sensitivity, several actions were taken.
Journalists with special interests in health or science
reporting were alerted when the results were about to
be released and invited to communication events. In
addition, the local community radio shows that ran dur-
ing the trials were used to communicate the findings
over a series of shows. Training of staff and, where pos-
sible, community representatives, in handling and
responding to media queries proved the most invaluable.
This was best demonstrated in the most recent trial,
during a pre-release meeting between investigators and
CAB members. At this meeting, all questions were
responded to and documented. CAB members were
then asked to think of the most difficult questions they
might be asked by community members or local jour-
nalists, and these were added to a list. CAB members
were then paired and asked to work through the ques-
tions and their responses, using an interview format.
This activity was repeated until CAB members felt com-
fortable with the questions and their responses. In the
subsequent discussion, CAB members articulated how
useful the exercise was for internalising and rehearsing
the trial messages. They also articulated how activities
such as these demonstrated the trust between research-
ers and the community.
Impact of evidence on policy
Given all this investment in communication, the results
of the trials themselves were disappointing. Overall, the
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trials showed that despite the observational evidence,
daily acyclovir was not sufficient to prevent HIV acquisi-
tion [16]. Moreover, although two trials showed that
acyclovir was able to reduce infectiousness (through
reductions in plasma and genital HIV viral loads)
[13,17], this was not sufficient to prevent HIV transmis-
sion [18]. An important finding from these two trials
was the observation that daily acyclovir reduces plasma
HIV viral load which was ultimately shown to result in
modest but significant delays in HIV disease progression
and death. Of value, although expected, was the finding
that the trials showed an impact of daily acyclovir on
the frequency of genital ulcer episodes, and in the episo-
dic therapy trial, acyclovir improved ulcer healing by an
average of two to three days [19].
While the South African trials were essential for
answering important research questions, the results
meant that no change in HIV prevention policy was
required. Although not the primary focus in all cases,
these results did influence guidelines around case man-
agement of genital ulcer disease (GUD), and acyclovir is
now recommended for the first-line management of
GUD at the primary health care level. New data regard-
ing the potential use of acyclovir as an intervention to
delay disease progression in HIV-positive people not yet
eligible for anti-retroviral therapy did emerge and has
important policy implications for HIV management.
However, more data is needed to understand the finan-
cial implications and potential risks for the emergence
of HSV or HIV resistance before policy is likely to be
changed.
Discussion
Despite the disappointing results, these trials were
important because they demonstrated the need for using
the best research designs to answer important scientific
questions without ambiguity. Several lessons were learnt
during the results communication process which may be
of relevance for the communication of research results
more generally.
The first finding is that contextual factors strongly
influenced the approach to communication. In response
to the mistrust and lack of understanding about research
at the time, researchers engaged in an intensive approach
to communication. This approach was aimed primarily at
addressing what was perceived as a lack of knowledge
and skills to understand and interpret the results of ran-
domised controlled trials. Regular interactions from the
start of the trials, using multiple approaches in combina-
tion, appear to have been the key to success. Using a
range of communication methods ensured that the
broadest possible audience was reached. Using opportu-
nities to repeat the message through different formats
helped to correct misunderstandings and reinforce the
trial results. Strategies which involved personal contact
like the CAB meetings, stakeholder events, or the
unblinding visits were very important in the success of
communication. The importance of personal contact and
opportunities for two-way communication have been
highlighted by other authors [20,21].
Focussing on communications from the start of the
trials gave time to build understanding, as well as trust.
Through text messaging, home visits, community events
and the radio shows, the trials were made more visible
and familiar to ordinary citizens. Through the CABs, the
trials were opened up to scrutiny by community mem-
bers. These strategies all made the research more acces-
sible, built a greater understanding of the research
process, and facilitated the development of more perso-
nal relationships between the researchers and the study
communities. During the life of the trials, participants
and community members developed a sense of owner-
ship of the research and became invested in its success-
ful completion, rather than in just its success. In this
context, researchers could then talk about the uncer-
tainty of trial outcomes and prepare participants and
communities for these different outcomes. This prepara-
tion was critical in the subsequent acceptance by partici-
pants and communities of the actual trial results
because the range of trial outcomes had been discussed,
debated and understood.
The second finding is that researchers actively mana-
ged the communications process. In doing this, they
became agents of social change. For the authors, while
the idea of active engagement was intentional, the con-
cept of social change was not conscious at the time.
What the case study shows is that the researchers recog-
nised that the government of the day might not act on
the evidence generated from the trials. It shows that
they understood that civil society responses to an
intractable government were part of the South African
experience. Researchers recognised that the evidence
from the trials alone might not be sufficient to change
policy, and community mobilisation and an informed
media might be needed to ensure the translation of evi-
dence to policy. In response, researchers stepped outside
of their traditional role and actively engaged in the com-
munication process. In so doing, they were required to
respond to the legacies of apartheid, that is the lack of
knowledge, the lack of skill and the lack of trust in
science. In this context, knowledge is power. While the
communication activities were ostensibly aimed at
increasing knowledge about research, they indirectly
shifted the balance of power in favour of participants
and communities.
The case study demonstrates several examples where
activities aimed at empowering stakeholders were
attempted. Participants and communities were provided
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with information about the trials, including the ratio-
nale, the design, and an explanation of the key concepts
of the trials as well as the results. Skills building work-
shops around communicating key messages from the
trial gave participants and community members confi-
dence to speak about the trial results and experience
from their perspective. Through the stakeholder events
as well as the radio shows, participants and community
members were given access to a range of platforms that
they might not otherwise have had access to, to tell
their stories. Through the results communication pro-
cess, groupings who might not ordinarily meet like gov-
ernment officials, community members and researchers
were brought together to discuss and consider the trial
results together. In these situations, participants and
community members were given opportunities to be
heard directly by policy-makers and service providers.
Government institutions and the media were also sup-
ported through these processes. SANAC, which had
been weakened by the debates around the origins of
AIDS, was now supported. By recognising the leadership
of key government institutions and actively engaging
with them, by sharing information and knowledge with
politicians, government officials and regulatory authori-
ties about the trials, researchers were able to build cred-
ibility and trust in the research results when they
became public. In engaging with the media, there was
recognition of the need to build a partnership with
trusted journalists who could be relied upon to present
clear messages about the trials and their results. By sup-
porting a community radio station throughout the trial,
community journalists were empowered to broadcast
clear messages about research with local relevance.
The process of empowerment was not without chal-
lenges. The communications approach was aimed at
strengthening the trial and not an end in itself. The
resources available for these activities came from the
trial. As such, the researchers were not in the best posi-
tion to fully address the social and economic inequalities
observed in the study communities. During the trials,
there were times when these inequalities became a
source of conflict. For example, there were situations
where individual CAB members tried to hijack the trial
activities for their own gain, e.g. insisting on catering
contracts during participant events. Some CAB mem-
bers became so invested in the trial activities that they
felt they should be paid as research staff. To community
members and participants, the researchers appeared to
have access to money and other resources. It was almost
expected that some individuals would try to take advan-
tage of that situation. For research staff, particularly
field workers who often lived in these communities,
these were uncomfortable situations. In all cases, these
conflicts were resolved through dialogue. Discussions
focussed on the scope and limitations of the research
organisation in terms of resources. Where real needs
were identified, researchers used their position and net-
works to identify partner organisations working on pov-
erty and development issues to assist with these needs.
Including local government, religious groups and other
community organisations in the CAB was helpful in this
regard. It was also was interesting to observe that in
situations where individuals were perceived to be acting
in their own interests, good sense prevailed and other
CAB members were instrumental in resolving these con-
flicts and re-focussing attention on the trial and the
greater goal of HIV prevention, with very little interven-
tion by the researchers. Even with this intensive
approach to communications, the research teams were
not able to reach all participants to communicate the
research results. Although policies around the treatment
of GUD changed, we were not able to influence as easily
the way in which programmes were delivered. While
arrangements were made for participants to have access
to treatment and care after the trial, participants com-
plained about the quality of service provided in public
sector clinics.
Finally, this case study provides an opportunity to
reflect more generally on approaches taken to commu-
nicating the results of clinical research. This is an emer-
ging field, and there is very little published on this topic
in relation to countries outside North America and Eur-
ope. Some authors suggest that more evidence is needed
about appropriate methods for disseminating trial
results to participants and the impact of these, arguing
that providing results of trials to trial participants is not
straightforward and constitutes an intervention in its
own right [22-24]. In a recent review which summarised
the effects of communicating research results on partici-
pants in 28 studies, investigators and the research enter-
prise, the authors noted that despite the growing
number of national and international policies and guide-
lines concerning the duty to return research results,
debate still continued over the scope and limits of inves-
tigator’s responsibilities in this regard. Communicating
results was found to be highly desirable to participants
and to a lesser extent investigators, but the mechanisms
for doing this were poorly developed [25]. All of the stu-
dies reviewed were conducted in North America or Eur-
ope, and the majority involved cancer or genetic studies.
The HIV prevention field has been concerned with
how best to protect the rights of trial participants and
communities when inequalities in power, wealth, educa-
tion and literacy exist between the individuals proposing
to conduct research and those who are hardest hit by
the HIV epidemic. For the trials reported in this case
study, very little explicit official guidance was given on
the communication of research results at the onset of
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the trials. In an updated edition of the South African
Good Clinical Practice Guidelines which became avail-
able shortly before the results of the first trial in the
case study were reported, investigators are regarded as
having “an ethical obligation to disseminate research
results, whether positive or negative, in a timely man-
ner” [26]. Further advice suggests that results be com-
municated to participants and interested community
members using appropriate formats but beyond that
there is little guidance for investigators. The South Afri-
can investigators of the cellulose sulphate microbicide
trial published their experience of communicating the
early closure of a trial. This provided practical insights
particularly around dealing with the media [11]. In
November 2007, UNAIDS published guidelines on Good
Participatory Practice for Biomedical HIV prevention trials
[27]. These guidelines aimed to provide systematic gui-
dance on the roles and responsibilities of entities funding
and conducting HIV prevention trials towards participants
and communities. An earlier version of this document
released in 2000 led to many HIV prevention trials adopt-
ing a community engagement approach. The 2007 docu-
ment consolidated the experiences of many of these trials
conducted in a wide range of contexts and attempts to
give more specific guidance for sponsors and investigators
on how to engage with communities. While this document
is much more practical in its advice, concerns have been
raised by investigators in low- and middle-income coun-
tries that these guidelines are aspirational and will remain
so as long as resources are not provided to support com-
munity engagement in trials [28].
The resources required for the communication of
research results remain a concern for investigators gen-
erally. There is little published data on the costs of com-
municating research results to participants. In this case
study, all communication costs were covered by trial
funds, in keeping with UNAIDS recommendations [27].
The largest cost item apart from staff costs was the
radio show which was shared by several trials. All com-
munication activities were conducted by trial staff as
part of their trial responsibilities. We invested resources
in training trial staff in communications and media
handling rather than employing individuals with specia-
list media and communications skills. This approach
made it possible for trial staff to communicate the
research results in the local languages at the site,
allowed for the experience of research results communi-
cation to be transferred from one project to the next
and expanded the pool of individuals available to talk
about the research results in a variety of settings. Even
in the context of limited funds, there is a lot that can be
achieved in the way of communications with a team of
experienced staff. There are legitimate concerns that
these activities may distract researchers from the
academic expectations that they publish. While this view
may be true in the short-term, the initial investments in
time and energy lay the foundation for lasting produc-
tive research partnerships.
Conclusions
Despite disappointing trial results for the field of HIV
prevention, the investments in communicating research
results and building partnerships were essential for
building trust between researchers, communities and
policy-makers, creating a more enabling environment
for future research to take place.
Acknowledgements
The authors would like to thank Phumlaphi Masuku, Lucky Molefe, the
community health workers and other trial staff who worked tirelessly to
ensure that the research results were communicated. We acknowledge the
participants, CABs and community organisations that contributed to these
trials. We thank all the people from government, civil society and research
organisations who participated in the dissemination events for these trials
for their time. We are grateful to the international investigators and sponsors
of the trials who provided the opportunity for these experiences. We thank
Joanne Crichton and David Ross for their useful advice and suggestions on
the manuscript.
This work was supported in part by the Department for International
Development (DFID)-funded Research Programme Consortium (RPC) on
Research and Capacity Building on Sexual & Reproductive Health and HIV in
Developing Countries [grant RPC HD3]. The views presented in this
manuscript are those of the authors and do not necessarily represent the
official position of DFID.
This article has been published as part of Health Research Policy and Systems
Volume 9 Supplement 1, 2011: Strengthening the research to policy and
practice interface: exploring strategies used by research organisations
working on sexual and reproductive health and HIV/AIDS. The full contents
of the supplement are available online at http://www.health-policy-systems.
com/supplements/9/S1.
Author details
1Reproductive Health & HIV Research Unit, University of the Witwatersrand,
South Africa. 2Department of Infectious & Tropical Diseases, London School
of Hygiene & Tropical Medicine, UK.
Author contributions
SDM conceived and drafted the first version of the manuscript. JS, PM, and
HR provided data and/or useful insights and critically reviewed the
manuscript.
Competing interests
The authors declare that they have no competing interests.
Published: 16 June 2011
References
1. Report on the global HIV/AIDS epidemic 2008. [http://data.unaids.org/
pub/GlobalReport/2008/jc1510_2008_global_report_pp29_62_en.pdf].
2. United Nations Millennium Declaration (Resolution A/55/2). [http://www.
un.org/millennium/declaration/ares552e.pdf].
3. Fassin D, Schneider H: The politics of AIDS in South Africa: beyond the
controversies. BMJ 2003, 326(7387):495-497.
4. Niehaus I, Jonsson G: Dr. Wouter Basson, Americans, and wild beasts:
men’s conspiracy theories of HIV/AIDS in the South African Lowveld.
Med Anthropol 2005, 24(2):179-208.
5. Stadler J: Rumor, gossip and blame: implications for HIV/AIDS prevention
in the South African lowveld. AIDS Educ Prev 2003, 15(4):357-368.
6. Butler A: South Africa’s HIV/AIDS policy, 1994-2004: How can it be
explained? Afr Aff (Lond) 2005, 104(417):591-614.
Delany-Moretlwe et al. Health Research Policy and Systems 2011, 9(Suppl 1):S8
http://www.biomedcentral.com/1478-4505/9/S1/S8
Page 8 of 9
7. Hlongwa W: Medical research trial guinea pigs contract HIV. City Press
Johannesburg: News24; 2007.
8. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ: Herpes
simplex virus 2 infection increases HIV acquisition in men and women:
systematic review and meta-analysis of longitudinal studies. AIDS 2006,
20(1):73-83.
9. Celum CL, Robinson NJ, Cohen MS: Potential effect of HIV type 1
antiretroviral and herpes simplex virus type 2 antiviral therapy on
transmission and acquisition of HIV type 1 infection. J Infect Dis 2005,
191(Suppl 1):S107-114.
10. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A:
Randomized, controlled intervention trial of male circumcision for
reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005,
2(11):e298.
11. Ramjee G, Govinden R, Morar NS, Mbewu A: South Africa’s experience of
the closure of the cellulose sulphate microbicide trial. PLoS Med 2007,
4(7):e235.
12. Staff: AIDS Shock! Daily Sun Johannesburg: Media24; 2007.
13. Nagot N, Ouedraogo A, Foulongne V, Konate I, Weiss HA, Vergne L,
Defer MC, Djagbare D, Sanon A, Andonaba JB, et al: Reduction of HIV-1
RNA levels with therapy to suppress herpes simplex virus. N Engl J Med
2007, 356(8):790-799.
14. Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Baisley K, Mugeye K,
Tanton C, Ross D, Everett D, Clayton T, et al: Effect of herpes simplex
suppression on incidence of HIV among women in Tanzania. N Engl J
Med 2008, 358(15):1560-1571.
15. Saethre EJ, Stadler J: Gelling medical knowledge: innovative
pharmaceuticals, experience, and perceptions of efficacy. Anthropology &
Medicine 2010, 17(1):99-111.
16. Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S,
Cowan F, Casapia M, Ortiz A, Fuchs J, et al: Effect of aciclovir on HIV-1
acquisition in herpes simplex virus 2 seropositive women and men who
have sex with men: a randomised, double-blind, placebo-controlled trial.
Lancet 2008, 371(9630):2109-2119.
17. Delany S, Mlaba N, Clayton T, Akpomiemie G, Capovilla A, Legoff J, Belec L,
Stevens W, Rees H, Mayaud P: Impact of aciclovir on genital and plasma
HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-
controlled trial in South Africa. AIDS 2009, 23(4):461-469.
18. Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, Mujugira A,
Baeten JM, Mullins JI, Hughes JP, et al: Acyclovir and transmission of HIV-1
from persons infected with HIV-1 and HSV-2. N Engl J Med 2010,
362(5):427-39.
19. Paz-Bailey G, Sternberg M, Puren AJ, Markowitz LE, Ballard R, Delany S,
Hawkes S, Nwanyanwu O, Ryan C, Lewis DA: Improvement in healing and
reduction in HIV shedding with episodic acyclovir therapy as part of
syndromic management among men: a randomized, controlled trial. J
Infect Dis 2009, 200(7):1039-1049.
20. Innvaer S, Vist G, Trommald M, Oxman A: Health policy-makers’
perceptions of their use of evidence: a systematic review. J Health Serv
Res Policy 2002, 7:239-244.
21. Dorsey ER, Beck CA, Adams M, Chadwick G, de Blieck EA, McCallum C,
Briner L, Deuel L, Clarke A, Stewart R, et al: Communicating Clinical Trial
Results to Research Participants. Arch Neurol 2008, 65(12):1590-1595.
22. Dixon-Woods M, Jackson C, Windridge KC, Kenyon S: Receiving a summary
of the results of a trial: qualitative study of participants’ views. BMJ 2006,
332(7535):206-210.
23. Dinnett EM, Mungall MM, Gordon C, Ronald ES, Gaw A: Offering results to
research participants. BMJ 2006, 332(7540):549-550.
24. MacNeil SD, Fernandez CV: Offering results to research participants is
ethically right but not yet fully explored. BMJ 2006, 332:188-189.
25. Shalowitz DI, Miller FG: Communicating the results of clinical research to
participants: attitudes, practices, and future directions. PLoS Med 2008,
5(5):e91.
26. Department of Health: Guidelines for Good Practice in the Conduct of
Clinical Trials with Human Participants in South Africa. Pretoria:
Department of Health; 2006, 37.
27. UNAIDS: Good participatory practice : guidelines for biomedical HIV
prevention trials. Geneva; 2007, 1-66, UNAIDS/07.30E/JC1364E(English
original November 2007)edn.
28. Miller L, Bass E, Warren M, Grant D, Costelloe-Kuhn A, Feuer C, Fisher K:
Good participatory practice guidelines begin to take root. Retrovirology
2009, 6(Suppl 3):P225.
doi:10.1186/1478-4505-9-S1-S8
Cite this article as: Delany-Moretlwe et al.: Investing in the future:
lessons learnt from communicating the results of HSV/ HIV intervention
trials in South Africa. Health Research Policy and Systems 2011 9(Suppl 1):
S8.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Delany-Moretlwe et al. Health Research Policy and Systems 2011, 9(Suppl 1):S8
http://www.biomedcentral.com/1478-4505/9/S1/S8
Page 9 of 9
